Recurrent metastatic clear cell renal carcinoma with sarcomatoid dedifferentiation treated with surgery and Cabozantinib.

Autor:	Boustany J; Notre Dame des Secours University Hospital Center (CHUNDS), Byblos City, Lebanon.; Holy Spirit University of Kaslik (USEK), Jounieh, Lebanon., Abdessater M; Notre Dame des Secours University Hospital Center (CHUNDS), Byblos City, Lebanon.; Holy Spirit University of Kaslik (USEK), Jounieh, Lebanon., Hachem CE; Notre Dame des Secours University Hospital Center (CHUNDS), Byblos City, Lebanon.; Holy Spirit University of Kaslik (USEK), Jounieh, Lebanon., Khoury ZE; Notre Dame des Secours University Hospital Center (CHUNDS), Byblos City, Lebanon.; Holy Spirit University of Kaslik (USEK), Jounieh, Lebanon., Khoury WE; Notre Dame des Secours University Hospital Center (CHUNDS), Byblos City, Lebanon.; Holy Spirit University of Kaslik (USEK), Jounieh, Lebanon., Khoury RE; Notre Dame des Secours University Hospital Center (CHUNDS), Byblos City, Lebanon.; Holy Spirit University of Kaslik (USEK), Jounieh, Lebanon.
Jazyk:	angličtina
Zdroj:	Oncotarget [Oncotarget] 2020 May 19; Vol. 11 (20), pp. 1922-1928. Date of Electronic Publication: 2020 May 19 (Print Publication: 2020).
DOI:	10.18632/oncotarget.27543
Abstrakt:	Renal cell carcinoma with sarcomatoid dedifferentiation is an entity of RCC that has undergone an anaplastic transformation with both a carcinomatous and a sarcomatous component. The standard treatment in metastatic patients is immunotherapy. The aim of this article is to describe our case of metastatic recurrent RCC with sarcomatoid dedifferentiation in a 59 year old male patient treated with nephrectomy and multiple metastasectomies followed by Cabozantinib. Consecutive PET-CT scans showed no evidence of recurrence, three years after the last metastasectomy, and the patient is having currently a normal life. Sarcomatoid dedifferentiation remains a poor prognosis factor in RCC. Surgery for metastases followed by Cabozantinib may be a therapeutic option in metastatic young patients. However, a prospective randomized trial would be the best option to validate this approach. Competing Interests: CONFLICTS OF INTEREST The authors declare no conflicts of interest.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu